AKEBIA THERAPEUTICS, INC. Accounts Receivable, Allowance for Credit Loss, Recovery
AKEBIA THERAPEUTICS, INC. (AKBA) reported Accounts Receivable, Allowance for Credit Loss, Recovery of $0 for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-08.
Financial Statements › Notes › Accounts, Notes, Loans and Financing Receivable, Gross, Allowance, and Net
us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries · last filed 2025-05-08
- AKEBIA THERAPEUTICS, INC. accounts receivable, allowance for credit loss, recovery for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- AKEBIA THERAPEUTICS, INC. accounts receivable, allowance for credit loss, recovery for the quarter ending 2024-03-31 was $1.00K.
| Period end | Accounts Receivable, Allowance for Credit Loss, Recovery 3 month |
|---|---|
| 2025-03-31 | $0.00 10-Q · filed 2025-05-08 |
| 2024-03-31 | $1.00K 10-Q · filed 2025-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |